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MYC proteins bind globally to active promoters and
promote transcriptional elongation by RNA polymer-
ase II (Pol II). To identify effector proteins that
mediate this function, we performedmass spectrom-
etry on N-MYC complexes in neuroblastoma cells.
The analysis shows that N-MYC forms complexes
with TFIIIC, TOP2A, andRAD21, a subunit of cohesin.
N-MYC and TFIIIC bind to overlapping sites in
thousands of Pol II promoters and intergenic regions.
TFIIIC promotes association of RAD21 with N-MYC
target sites and is required for N-MYC-dependent
promoter escape and pause release of Pol II.
Aurora-A competes with binding of TFIIIC and
RAD21 to N-MYC in vitro and antagonizes associa-
tion of TOP2A, TFIIIC, and RAD21with N-MYC during
S phase, blocking N-MYC-dependent release of Pol
II from the promoter. Inhibition of Aurora-A in S phase
restores RAD21 and TFIIIC binding to chromatin and
partially restores N-MYC-dependent transcriptional
elongation. We propose that complex formation
with Aurora-A controls N-MYC function during the
cell cycle.
INTRODUCTION
The MYC family of transcription factors (MYC, N-MYC, and
L-MYC) has been causally implicated in the development of mul-Cell Repor
This is an open access article under the CC BY-Ntiple human tumors (Dang, 2012). MYC proteins bind to virtually
all promoters with an open chromatin structure as well as to
thousands of enhancers (Walz et al., 2014; Sabo` et al., 2014;
Lin et al., 2012; Nie et al., 2012). They stimulate transcription of
large groups of genes encoding, among others, proteins
involved in protein translation, cell cycle progression, and inter-
mediary metabolism and repress transcription of genes encod-
ing cell cycle inhibitory proteins as well as proteins involved in
cell adhesion and differentiation (Dang, 2012). In some settings,
MYCproteins act as ‘‘general amplifiers’’ that enhance transcrip-
tion of all actively transcribed protein-coding genes (Nie et al.,
2012; Lin et al., 2012).
During early transcription, RNA polymerase II (Pol II) goes
through a series of intermediate states that begin with the for-
mation of a closed promoter complex and end with the release
of Pol II from a promoter-proximal pause position into produc-
tive elongation (Michel and Cramer, 2013). To enhance tran-
scription, MYC proteins promote both recruitment of Pol II to
the promoter and its subsequent release into elongation (Rahl
et al., 2010; Jaenicke et al., 2016; Walz et al., 2014). Escape
from the promoter and pause release of Pol II are controlled
by sequential phosphorylation of Ser5 and Ser2 in the C-termi-
nal domain of Pol II and activation of MYC promotes phosphor-
ylation at both sites (Jonkers and Lis, 2015; Rahl et al., 2010;
Walz et al., 2014; Cowling and Cole, 2007). Known protein-pro-
tein interactions of MYC include the association with MAX,
which is required for binding to DNA (Blackwell et al., 1993),
the NuA4 histone acetylase complex (McMahon et al., 1998),
the p400 and BPTF chromatin-remodeling complexes (Richart
et al., 2016; Fuchs et al., 2001), and the PAF1C elongation com-
plex (Jaenicke et al., 2016). How MYC engages its differentts 21, 3483–3497, December 19, 2017 ª 2017 The Author(s). 3483
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cofactors to promote elongation and how this process is regu-
lated is largely unknown.
Deregulated expression of N-MYC is characteristic for suben-
tities of pediatric neuroblastoma andmedulloblastoma aswell as
for adult neuroendocrine and some hematopoietic malignancies
(Beltran, 2014). Like all MYC proteins, N-MYC is rapidly turned
over via the ubiquitin/proteasome system (Sjostrom et al.,
2005). The SCFFBXW7 ubiquitin ligase recognizes a phosphode-
gron that is part of a conserved domain called MYCBoxI
(Welcker et al., 2004). Replacing two phosphoresidues, T58
and S62, with alanine stabilizes N-MYC (Otto et al., 2009). S62
is phosphorylated by cyclin-dependent kinases and primes
phosphorylation of T58 by GSK3, resulting in cell cycle- and
growth factor-dependent proteasomal turnover of N-MYC
(Chesler et al., 2006; Sjostrom et al., 2005).
In multiple tumor entities, N-MYC is stabilized by complex for-
mation with Aurora-A (Otto et al., 2009; Dardenne et al., 2016).
Aurora-A is a serine/threonine kinase that is best known for its
role in centrosome function and mitosis (Marumoto et al.,
2005). Aurora-A binds to N-MYC directly via two domains that
flank the SCFFBXW7 phosphodegron and antagonizes degrada-
tion of N-MYC by SCFFBXW7 (Otto et al., 2009; Richards et al.,
2016). Although stabilization of N-MYC does not require
Aurora-A catalytic activity, Aurora-A inhibitors that distort the
kinase domain dissociate the N-MYC/Aurora-A complex and
destabilize N-MYC (Richards et al., 2016). These inhibitors
show therapeutic efficacy in N-MYC-driven tumor models and
are being tested in human patients (DuBois et al., 2016). We
have now analyzed protein complexes of N-MYC to understand
how N-MYC controls Pol II function and how association with
Aurora-A impacts N-MYC function.
RESULTS
Complexes of N-MYC with TFIIIC, TOP2A, and RAD21
To identify protein complexes of N-MYC in neuroblastoma cells,
we used SH-EP cells, which do not express endogenous N-MYC.
Using retroviral infection, we stably expressed HA-tagged wild-
type (WT) N-MYC (N-MYCwt) or N-MYCT58AS62A (N-MYCmut)
(Figure 1A). Immunoblots showed that levels of N-MYC in in-
fected cells were comparable with those found in a MYCN-
amplified neuroblastoma cell line, IMR-32 (Figure 1A). We
then performedmass spectrometry of complexes recovered af-
ter immunoprecipitation with a-hemagglutinin (a-HA) antibodies
and elution with a HA peptide using label-free quantification
(Figure 1B; Table S1). The analysis confirmed multiple well-vali-
dated interactions of N-MYC or MYC proteins, including inter-
actions with TRRAP, p400, BPTF, MAX, Aurora-A, and CDC73
(Figure S1A). In addition, the analysis identified interactions
with 5 of 6 subunits of the TFIIIC complex and topoisomerases
IIA and IIB (TOP2A and TOP2B). TFIIIC is both a general
transcription factor of RNA polymerase III and an architectural
protein that is localized at the border of topological domains
(Crepaldi et al., 2013; Van Bortle et al., 2014). TOP2A has
been implicated in relieving transcription-induced supercoiling
at highly active promoters (Kouzine et al., 2013).We speculated,
therefore, that these interactions may identify effector functions
of N-MYC.3484 Cell Reports 21, 3483–3497, December 19, 2017Immunoprecipitations using a-HA antibodies confirmed that
TFIIIC and TOP2Awere present in immunoprecipitates from cells
expressing N-MYC but not in control immunoprecipitates from
cells not expressing HA-tagged N-MYC (Figure S1B). Parallel
mass spectrometry demonstrated the presence of 5 of 6 sub-
units of TFIIIC and TOP2A in a-N-MYC immunoprecipitates but
not in control immunoprecipitates from MYCN-amplified neuro-
blastoma cells (Figure S1C). Multiple subunits of TFIIIC and
TOP2A were also detected in a-HA precipitates from U2OS cells
expressingHA-taggedMYCbut not control immunoprecipitates,
arguing that MYC, like N-MYC, associates with these proteins
(Figure S1D); this is consistent with a previous mass spectro-
metric analysis (Koch et al., 2007). Using an antibody that recog-
nizes TFIIIC5, we confirmed that TFIIIC associates with endoge-
nous N-MYC and, albeit more weakly, with TOP2A as well as
TOP2B inMYCN-amplified neuroblastoma cells (Figure 1C; Fig-
ure S1E). Notably, interactions of N-MYC with TFIIIC5 and
TOP2A were also observed in the presence of ethidium
bromide (EtBr), which disrupts DNA-dependent interactions
(Figure 1C). This observation precludes the possibility that the in-
teractions are indirectly mediated by DNA.
To identify domains of N-MYC that interact with TFIIIC and
TOP2A, we performed pull-down assays from cell lysates incu-
bated with recombinant FLAG-tagged peptides covering frag-
ments of the N-MYC N terminus (Figure 1D). These assays
showed that residues 1–137 are sufficient for binding to TFIIIC
and suggested that two regions of N-MYC that flank MYCBoxI,
but not MYCBoxI itself (peptides 46–89), mediate binding to
TFIIIC. Controls established that an equimolar amount of an un-
related FLAG-tagged protein (heterogeneous nuclear ribonu-
cleoprotein [hnRNP], amino acids 330–463) does not bind
TFIIIC5 (E.L., unpublished data). In parallel assays, we were un-
able to demonstrate that residues 1–137 of N-MYC are sufficient
for binding to TOP2A (E.L., unpublished data). Previous work has
demonstrated that TFIIIC co-localizes and associates with cohe-
sin and condensin complexes in different organisms (Van Bortle
et al., 2014; D’Ambrosio et al., 2008), prompting us to search for
the presence of these complexes in N-MYC immunoprecipi-
tates. Indeed, peptides of the kleisin component of the cohesin
complex, RAD21, were found in the mass spectrometry analysis
(Table S1), and we confirmed that both N-MYC expressed in
SH-EP cells and endogenous N-MYC in MYCN-amplified
IMR-5 cells associates with RAD21 (Figure 1E; Figure S1B).
Mapping of the interaction to the N-MYC N terminus showed
the same binding pattern as TFIIIC, suggesting that they co-exist
with N-MYC in the same complex (Figure 1D).
Like TFIIIC and RAD21, Aurora-A interacts with N-MYC via two
domains flanking MYCBoxI (Richards et al., 2016), raising the
possibility that Aurora-A competes with TFIIIC or RAD21 for
binding to N-MYC. Indeed, Aurora-A competed with both TFIIIC
and RAD21 for binding to the N-MYC N terminus (1–137) in pull-
down assays using FLAG-tagged peptides, whereas an equi-
molar amount of an unrelated protein, glutathione-S-transferase,
did not compete (Figure 1F). Immunoprecipitations from
MYCN-amplified neuroblastoma cells showed that TFIIIC,
RAD21, and Aurora-A were present in a-N-MYC immunoprecip-
itates (Figure 1E). In parallel assays, both N-MYC and, weakly,
TFIIIC, but not RAD21, were detectable in a-Aurora-A
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Figure 1. Complexes of N-MYC with TFIIIC,
TOP2A, RAD21, and Aurora-A
(A) Immunoblot documenting levels of ectopically
expressed (exo) N-MYCwt and N-MYCmut proteins
in stably infected SH-EP neuroblastoma cells
relative to endogenous N-MYC (endo) of IMR-32
MYCN-amplified neuroblastoma cells. Where
indicated, ectopically expressed proteins carry an
N-terminal HA tag (NT HA); hence, their molecular
weight is slightly larger than that of the endoge-
nous protein (n = 2).
(B) Results of mass spectrometry of a-HA immu-
noprecipitates of N-MYCwt and N-MYCmut com-
plexes. The axes show the normalized ratio of
peptides recovered in an a-HA immunoprecipita-
tion from cells expressing N-MYCwt or N-MYCmut
relative to an a-HA immunoprecipitation (IP) from
control cells. Dot size represents the MaxQuant
protein scores, which indicates the reliability of
protein identification (Cox and Mann, 2008).
(C) Immunoblots of a-N-MYC (left) and a-TFIIIC5
(right) immunoprecipitates from IMR-32 cells. The
input corresponds to 1% of the amount used for
the precipitation. Where indicated, ethidium bro-
mide (EtBr) was added to a final concentration of
1 mg ml1 to disrupt DNA-dependent interactions.
Non-specific immunoglobulin G (IgG) was used for
control immunoprecipitations (n = 3).
(D) Pull-down assays from cell lysates document-
ing binding of TFIIIC5 and RAD21 to FLAG-tagged
peptides spanning the indicated amino acids of the
N-MYCN terminus. The input corresponds to 0.6%
of the amount used for the precipitation (n = 2). The
graph at the bottom visualizes the binding of the
different N-MYC peptides. I/II indicate N-MYC se-
quences that mediate binding.
(E) Immunoblots of a-N-MYC (left) and a-Aurora-A
(right) immunoprecipitates from MYCN-amplified
IMR-5 cells. The input corresponds to 1% of the
amount used for the precipitation.Non-specific IgG
was used for control immunoprecipitates (n = 4).
(F) Pull-down assays from cell lysates document-
ing binding of TFIIIC5 and RAD21 to FLAG-tagged
N-MYC peptides spanning amino acids 1–137
upon competition with Aurora-A. Recombinant
Aurora-A protein was added in a concentration-
dependent manner from 0.25 to 5 molar equiva-
lents (Aurora-A/N-MYC peptide). 5 molar equiva-
lents of glutathione-S-transferase (GST) were
used as a control (n = 3).
See also Figure S1 and Table S1. n indicates the
number of independent biological replicas for
each experiment.immunoprecipitates (Figure 1E). We concluded that Aurora-A
and RAD21 form alternate complexes with N-MYC in cells,
whereas Aurora-A can remain associated with N-MYC and
TFIIIC via interactions that are outside of residues N-MYC
1–137 in vivo. To identify these domains in N-MYC, we used
overlapping peptide libraries in microarray format of N-MYC
and probed them with recombinant Aurora-A. Consistent with
these and previously published data (Richards et al., 2016), pep-
tides spanning amino acids 17–43 of N-MYC (9–43 in MYC) had
the highest affinity for Aurora-A. The arrays also revealed anadditional binding site with lower binding affinity for Aurora-A
in the C terminus of N-MYC, which spans amino acids 313–
339 (overlapping MYCBoxIV) and is conserved in MYC (amino
acids 306–331) (Figure S1F).
The interaction of Aurora-A with N-MYC is impaired by muta-
tions of T58 and S62 in N-MYC to alanine (Otto et al., 2009), and
immunoprecipitations from infected SH-EP cells confirmed this
observation (Figure S1B). Comparison of precipitates recovered
from cells expressing N-MYCwt with those from cells expressing
N-MYCmut suggested that phosphorylation of MYCBoxI mayCell Reports 21, 3483–3497, December 19, 2017 3485
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Figure 2. Chromatin Binding of N-MYC/
TFIIIC Complexes
(A) Genome browser tracks at the NME1 locus
illustrating chromatin association of the indicated
proteins. The positions of B- and E-boxes and of
CTCF motifs are indicated by vertical lines. The
upper input is for ChIP sequencing of N-MYC and
TFIIIC5; the lower input is for RAD21 and CTCF.
(B) Top: Venn diagram documenting genome-wide
overlap of N-MYC and TFIIIC5 binding sites in
IMR-5 neuroblastoma cells. The p value was
calculated using a permutation test. Bottom: dia-
gram showing the location of N-MYC/TFIIIC5 sites
in the genome.
(C) De novo motif search in N-MYC- and/or
TFIIIC5-bound regions. In overlapping sites, both
peak regions were analyzed. The numbers indi-
cate the percentage of sites in which the indicated
motif was found. E values for enrichment of the
respective motif are shown in Figure S2D. Motifs
are only shown if the enrichment was significant.
(D) Central enrichment of E-box, CTCF, and AP2a
(as a negative control) motifs in the N-MYC peak of
N-MYC/TFIIIC5 joint sites in Pol II promoters. The
E value is calculated by a binominal test and
adjusted for the number of motifs tested.
(E) Heatmap showing occupancy of N-MYC,
TFIIIC5, RAD21, andCTCF on overlappingN-MYC/
TFIIIC sites in IMR-5 cells. Samples are normalized
to the same number of mapped reads, and peaks
are sorted according to N-MYC binding.
(F) Boxplot documenting occupancy of the indi-
cated proteins at joint N-MYC/TFIIIC5 binding
sites (n = 1,630) and at N-MYC binding sites
lacking TFIIIC5 (n = 2,406) located in promoters of
Pol II genes. The number of readswas counted in a
region of ± 100 bp around the N-MYC peak sum-
mit.
See also Figure S2. n indicates the number of
independent biological replicas for each experi-
ment.affect the interaction with TFIIIC (Figure 1B), but immunoprecip-
itations from SH-EP cells did not reveal significant differences in
the interactions of N-MYCwt and N-MYCmut with RAD21, TFIIIC5,
and TOP2A (Figure S1B).
Joint N-MYC/TFIIIC Chromatin Binding Sites
TFIIIC binds to promoters transcribed by RNA polymerase III and
is an architectural protein complex that binds to thousands of
ETC (extra TFIIIC) sites throughout the genome that are indepen-
dent of RNA polymerase III (Moqtaderi et al., 2010; Oler et al.,
2010). To understand whether N-MYC and TFIIIC bind to over-
lapping sites on chromatin, we performed chromatin immuno-
precipitation (ChIP) coupled with high-throughput sequencing
(ChIP sequencing) using antibodies directed against N-MYC
and TFIIIC5. Inspection of individual genes revealed the pres-
ence of both proteins in close vicinity to each other at multiple3486 Cell Reports 21, 3483–3497, December 19, 2017transcription start sites (Figure 2A; Fig-
ure S2A). Global analyses identified a to-
tal of 2,053 sites with overlapping peaks,and statistical analyses showed that this overlap is highly signif-
icant (Figure 2B) (p < 106, calculated using a permutation test
with 1.0 3 106 iterations). The median distance between peak
summits at all joint sites was 39 bp (Figure S2B). Of these sites,
151 were found at tRNA genes; this is expected because MYC
proteins bind to tRNA genes (Gomez-Roman et al., 2003). In
addition, overlapping N-MYC/TFIIIC binding sites were found
at 1,165 promoters transcribed by Pol II and at 737 intra- and in-
tergenic sites. At core promoters transcribed by Pol II, N-MYC
binding peaked at transcription start sites, and TFIIIC binding
peaked with a slightly larger median distance of 80 bp 50 of
N-MYC binding sites, suggesting that joint sites may have a
defined orientation (Figure S2C).
MYC proteins bind to E-box sequences (CAC(A/G)TG) as part
of a heterodimeric complex with MAX (Blackwell et al., 1993).
Consistently, a de novo motif search identified E-boxes as a
predominant motif enriched in N-MYC binding sites in Pol II pro-
moters and at N-MYC/TFIIIC joint intergenic sites (Figure 2C;
Figure S2D). TFIIIC promotes binding to a sequence termed
A-box at tRNA promoters that are not present at ETC sites (Fig-
ure 2C; Figure S2D; Moqtaderi et al., 2010). In addition, TFIIIC
binds to a sequence termed B-box that is present in tRNA pro-
moters and in ETC sites and the de novomotif search confirmed
these observations (Figure 2C; Figure S2D; Moqtaderi et al.,
2010). B-boxes were also found in overlapping N-MYC/TFIIIC
sites in core promoters.
In addition to TFIIIC, ETC sites are also bound by the CTCF
transcription factor (Moqtaderi et al., 2010; Oler et al., 2010; Car-
rie`re et al., 2012; Vietri Rudan and Hadjur, 2015). Indeed, a de
novo motif search analysis identified a centrally enriched
consensus motif for CTCF at joint N-MYC/TFIIIC binding sites
(Figures 2C and 2D; Figures S2D–S2F). ChIP sequencing
confirmed the presence of CTCF at 936 of 2,053 joint N-MYC/
TFIIIC binding sites and showed a much lower occupancy at
N-MYC sites that do not bind TFIIIC (Figures 2E and 2F; Fig-
ure S2G). We concluded that N-MYC is present at previously
characterized TFIIIC binding sites both in RNA polymerase III
promoters and at ETC sites.
N-MYC and TFIIIC Promote Chromatin Association of
RAD21 at Joint Binding Sites
CTCF binding sites define contact points for RAD21/cohesin-
mediated chromosomal interactions (Ghirlando and Felsenfeld,
2016). Consistent with this notion, ChIP sequencing showed
that RAD21 was present at virtually all (22,642 of 23,479)
CTCF-bound sites and at 1,328 of 2,053 joint N-MYC/TFIIIC sites
(Figures 2E and 3A). RAD21 occupancy was much lower at
N-MYC sites that do not bind TFIIIC (Figure 2F). We also
observed that endogenous TFIIIC5 robustly co-immunoprecipi-
tated endogenous RAD21 (Figure 3B). Because RAD21/cohesin
complexes do not bind DNA directly, these observations raised
the question of whether TFIIIC or N-MYCaffects chromatin asso-
ciation of each other and of RAD21. We therefore performed
ChIP experiments in cells stably expressing doxycycline-induc-
ible short hairpin RNAs (shRNAs) targeting either TFIIIC or
N-MYC. Depletion of TFIIIC5 had little effect on steady-state
levels of N-MYC, RAD21, Aurora-A, and the DNA binding subunit
TFIIIC2 but led to a small reduction in TFIIIC1 levels (Figure 3C;
Figure S3A; Shen et al., 1996). As expected, we observed
reduced binding of TFIIIC5 at multiple N-MYC-bound loci (Fig-
ure 3D). Depletion of TFIIIC5 had no effect on binding of
N-MYC but reduced binding of RAD21 at almost all tested joint
binding sites, demonstrating that TFIIIC5 promotes binding of
RAD21 (Figure 3D). In contrast, depletion of TFIIIC5 had no effect
on RAD21 association with sites that were not bound by TFIIIC
and N-MYC (Figure S3B). Notably, shRNA-mediated depletion
of TFIIIC5 strongly reduced TFIIIC5 occupancy at sites tran-
scribed by Pol II, but TFIIIC5 binding to tRNA sites wasmore sta-
ble (Figure S3C). Although RAD21 is not detected at tRNA genes
(Oler et al., 2010; Moqtaderi et al., 2010), the stable binding of
TFIIIC5 to tRNA encoding genes precluded an unequivocal
determination of whether TFIIIC5 promotes binding of N-MYC
to tRNA genes. We also depleted TFIIIC2 and found that this
has no effect on either N-MYC or RAD21 binding to joint sites,arguing that not all subunits of TFIIIC are limiting for chromatin
association of RAD21 (Figures S3A and S3D). Depletion of
N-MYC using a doxycycline-inducible shRNA reduced binding
of N-MYC to most joint sites and significantly reduced binding
of both TFIIIC5 and of RAD21 to some sites, although the
extent of reduction was more variable than observed after
TFIIIC5 depletion (Figures 3E and 3F). In contrast, depletion of
N-MYC did not decrease RAD21 association with sites that
were not bound by TFIIIC and N-MYC (Figure S3E). Taken
together, the results suggest a hierarchy of chromatin binding
in which N-MYC contributes to recruitment of both TFIIIC5 and
RAD21 and TFIIIC5 is required for association of RAD21 with
joint binding sites.
Transcriptional Regulation by N-MYC and TFIIIC/RAD21
To determine whether TFIIIC5 and RAD21 are required for the
transcription of N-MYC target genes, we depleted either pro-
tein in IMR-5 cells using specific siRNAs. Control immunoblots
are shown in Figure 4A. RNA sequencing of two independent
samples for each protein showed a significant overlap of genes
regulated in response to depletion of either protein (Figure 4B).
Gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) showed that multiple well-characterized sets of MYC-
activated target genes were significantly downregulated upon
depletion of TFIIIC5 or RAD21; in contrast, only few gene
sets were significantly upregulated upon depletion of TFIIIC5
or RAD21 (Figures 4C and 4D). GSEA showed that the most
consistently downregulated gene sets encoded proteins
involved in cell cycle progression, DNA replication, nucleotide
metabolism, and telomere biology (Figure 4D). Comparison
with expression profiles obtained after shRNA-mediated
depletion of N-MYC in neuroblastoma cells (Valentijn et al.,
2012) confirmed that expression of these genes is sensitive
to depletion of N-MYC (Figures 4C and 4E). Furthermore,
expression of gene sets that are sensitive to depletion of
TFIIIC, RAD21, and N-MYC strongly correlated with MYCN
amplification and advanced tumor stage in neuroblastoma,
both of which are characteristic features of aggressive tumors
with a poor prognosis (Figure 4F; Molenaar et al., 2012). We
concluded that TFIIIC and RAD21 are required for expression
of a subset of N-MYC target genes that are characteristic for
MYCN-amplified neuroblastoma tumors. Consistent with these
effects on gene expression, shRNA-mediated depletion of
TFIIIC5 protein suppressed the growth of neuroblastoma cells
(Figure S4A), although it had little effect on the expression of
two tRNA genes we tested (Figure S4B). Notably, growth sup-
pression by depletion of TFIIIC5 was independent of MYCN
amplification (Figure S4A), arguing that TFIIIC5 also has essen-
tial functions in non MYCN-amplified cells. Most likely, the re-
sidual growth of IMR-5 cells after shRNA-mediated depletion
of TFIIIC5 was due to incomplete removal of TFIIIC5 because
multiple sgRNAs targeting TFIIIC5 eliminated cell growth (Fig-
ure S4C). This is consistent with the demonstration that sub-
units 1–5 of TFIIIC, RAD21, and TOP2A have been identified
as essential proteins in genome-wide CRISPR-based loss-of-
function screens (Hart et al., 2015). Depletion of TFIIIC5
caused little apoptosis and, like depletion of N-MYC (Otto
et al., 2009), delayed progression through all phases of theCell Reports 21, 3483–3497, December 19, 2017 3487
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Figure 3. Assembly of N-MYC/TFIIIC and RAD21 Complexes on Chromatin
(A) Venn diagram documenting genome-wide overlap of N-MYC/TFIIIC5 joint binding sites with RAD21 binding sites. The p value was calculated using a per-
mutation test with 100,000 iterations.
(legend continued on next page)
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Figure 4. Gene Regulation by N-MYC,
TFIIIC, and RAD21
(A) Immunoblots documenting levels of the indi-
cated proteins 48 hr after transfection of specific
siRNAs. Duplicate samples are shown, both of
which were used for RNA sequencing. All lanes are
from the same exposure of a single immunoblot.
(B) Venn diagrams documenting the overlap of
upregulated (top) and downregulated (bottom)
genes after depletion of TFIIIC5 or RAD21 in IMR-5
neuroblastoma cells. The p values were calculated
using a Monte Carlo simulation with 100,000 per-
mutations and all expressed genes (n = 17,450) as
the basis.
(C) Correlation of gene sets that change in
expression upon depletion of N-MYC with the
aggregate of changes in response to siRNA-
mediated depletion of RAD21 and TFIIIC5. Each
dot reflects a gene set. A light gray color indicates
that the expression change of a gene set was not
statistically significant. Published sets of MYC
target genes are colored.
(D) Examples of gene sets that are downregulated
in response to depletion of both RAD21 and
TFIIIC5. NES is the normalized enrichment score,
indicating direction and extent of regulation.
(E) Boxplots documenting changes in expression
of selected gene sets upon depletion of N-MYC
using a Dox-inducible shRNA in IMR-32 neuro-
blastoma cells.
(F) Heatmap illustrating stage-specific expression
of N-MYC/TFIIIC/RAD21-regulated genes sets in
human neuroblastoma cells. The black bars in the
first row indicate MYCN amplification status.
See also Figure S4. n indicates the number of in-
dependent biological replicas for each experiment.cell cycle; hence, fluorescence-activated cell sorting (FACS)
analyses did not detect a major shift in cell cycle distribution
(Figure S4D).(B) Immunoblots of a-TFIIIC5 immunoprecipitates from IMR-5 cells. The input corresponds to 1% of the amou
used for control immunoprecipitates. Where indicated, CD532 (1 mM) was added to cells 4 hr prior to immu
(C) Immunoblot showing levels of the indicated proteins in response to depletion of TFIIIC5. IMR-5 cells expre
were treated with doxycycline (Dox) for 48 hr or with ethanol (EtOH) as a control (n = 3).
(D) ChIP experiments documenting binding of TFIIIC5, N-MYC, and RAD21 to the indicated loci upon dep
triplicates from one experiment (n = 2).
(E) Immunoblot showing levels of the indicated proteins in response to depletion of N-MYC. IMR-5 cells expre
were treated with Dox for 48 hr or with EtOH as a control (n = 3).
(F) ChIP experiments documenting binding of TFIIIC5, N-MYC, and RAD21 to the indicated loci upon dep
triplicates from one experiment (n = 2).
See also Figure S3. n indicates the number of independent biological replicas for each experiment.
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Association
Aurora-A has been implicated in cell cycle
progression, prompting us to analyze
complex formation between N-MYC and
Aurora-A throughout the cell cycle in a
semiquantitative manner using proximity
ligation assays (PLAs) (So¨derberg et al.,
2006). In PLAs, a rolling circle amplifica-tion using oligonucleotides bound to secondary antibodies gen-
erates a signal that appears as a fluorescent dot when two anti-
gens are in proximity of each other. Controls using a N-MYCnt used for the precipitation. Non-specific IgG was
noprecipitation (n = 3).
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Figure 5. Regulation of N-MYC Transcription Complexes during the Cell Cycle
(A) Representative pictures from proximity ligation assays (PLAs) documenting complex formation between N-MYC and Aurora-A in IMR-5 cells after release
from a double thymidine block. Non-synchronized cells are shown as a control (Ctr). Nuclei were stained using Hoechst. Red dots showPLA signals resulting from
N-MYC/Aurora-A interactions (n = 3).
(legend continued on next page)
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antibody in SH-EP cells that do not express N-MYC (Figure S5A)
or using no primary antibody (Figure S5B) established that the
signals observed in these assays are specific. We used either
a release from a double thymidine block (Figure S5C) or re-stim-
ulation of serum-starved cells (Figure S5D) to synchronize cells.
In both experimental settings, Aurora-A predominantly associ-
ated with N-MYC during the S phase of the cell cycle, and com-
plex formation was regulated independently of changes in over-
all N-MYC and Aurora-A protein levels (Figures 5A, 5B, and 5E;
Figures S5E and S5F). We next tested whether association of
N-MYC with cofactors changes throughout the cell cycle.
Neither the association of N-MYC with p400 and TRRAP, which
ismediated byMYCBoxII (amino acids 128–143), nor the interac-
tionswith the PAF1 components CTR9 andCDC73, for which the
interaction domains are unknown, varied throughout the cell cy-
cle (Figure S5G). In contrast, association of RAD21 with N-MYC
was essentially absent during S phase (Figures 5C–5E). Similarly,
associations of N-MYC with TOP2A and TFIIIC5 changed during
cell cycle progression and were significantly lower in S phase
(Figures 5C–5E; Figure S5H). ChIP experiments from cells har-
vested in G1 and S phase showed that association of N-MYC
with joint binding sites was essentially equal in both cell cycle
phases, whereas chromatin association of RAD21 was strongly
reduced in S relative to G1 phase (Figure 5F). Chromatin associ-
ation of TFIIIC was also reduced in S phase, but the extent of
decrease was more variable between different gene loci. We
concluded that complex formation of N-MYC with RAD21,
TFIIIC, and TOP2A and chromatin binding of RAD21 and TFIIIC
are reduced during S phase.
Aurora-A Antagonizes N-MYC/RAD21 Complex
Formation in S Phase
We showed previously that association with N-MYC activates
the catalytic activity of Aurora-A (Richards et al., 2016), and
large-scale proteomic analyses show that multiple proteins
associated with N-MYC, including TFIIIC2 and TOP2A, are phos-
phorylated in an Aurora-A-dependent manner in vivo (Ketten-
bach et al., 2011). These findings, and the observation that
Aurora-A competes with association of RAD21 with N-MYC,
led us to hypothesize that Aurora-Amay antagonize complex for-
mation of N-MYC with RAD21, TOP2A, and, potentially, TFIIIC
during S phase. To test this, we used three structurally well-char-
acterized Aurora-A inhibitors to acutely antagonize Aurora-A
(Figure 6A; Richards et al., 2016). Of the inhibitors used,
MK-5108 is a purely catalytic Aurora-A inhibitor that does not
alter the conformation of Aurora-A and does not affect complex
formation with N-MYC. MLN8237 inhibits both the catalytic(B) Quantification of the PLA shown in (A). The percentage of cells in S phase
representative experiment (n = 3).
(C) Representative FACS profiles of propidium iodide (PI)-stained cells docume
thymidine block.
(D) Representative pictures from PLAs documenting complex formation betweenN
after release from a double thymidine block. Nuclei were stained using Hoechst.
(E) Quantification of PLAs shown in (A) and (D). Bars show mean + SD of technica
(F) ChIP of IMR-5 cells documenting chromatin association of N-MYC, RAD21, a
double thymidine block. Error bars show SD of technical triplicates from one rep
See also Figure S5. n indicates the number of independent biological replicas foactivity of Aurora-A and moderately distorts the N-MYC/
Aurora-A complex, enhancing degradation of N-MYC by
FBXW7 in mitosis. CD532 strongly distorts the Aurora-A struc-
ture, dissociates the N-MYC/Aurora-A complex, and induces
subsequent degradation of Aurora-A and N-MYC (Richards
et al., 2016). We confirmed that CD532 causes a proteasome-
dependent decrease in N-MYC and Aurora-A levels (Figures
S6A and S6B). In contrast, CD532 had no effect on complex for-
mation of TFIIIC5 with RAD21 (Figure 3B).
PLA assays from cells released for 4 hr from a double thymi-
dine block into S phase showed that MK-5108 and MLN8237
enhanced interactions of N-MYC with TFIIIC5, TOP2A, and,
albeit more weakly, RAD21 (Figures 6B and 6C). In these assays,
MK-5108 had the strongest effect. CD532 and MLN8237 had
smaller and more variable effects in PLAs with TOP2A, RAD21,
and TFIIIC5, most likely because the observed signals reflect a
combination of the decrease in N-MYC levels and an increase
in interaction (Figures 6A–6C). The data argue that Aurora-A-
dependent phosphorylation antagonizes interactions of N-MYC
with all three proteins.
ChIP and ChIP sequencing showed that chromatin associa-
tion of N-MYC decreased in response to CD532, consistent
with the effects on protein levels (Figures 6D and 6E; Fig-
ure S6C). In contrast, CD532 globally increased TFIIIC binding
to chromatin (Figure 6D; Figure S6D), and the number of joint
N-MYC/TFIIIC binding sites increased to 7,994 in the pres-
ence of CD532 (Figure S6E; note that N-MYC binding to chro-
matin remains detectable at virtually all sites after 4 hr of
CD532 treatment). ChIP assays confirmed that CD532
enhanced stable chromatin binding of TFIIIC and RAD21 at
joint binding sites, whereas the effects of MLN8237 and MK-
5108 were weak for most sites (Figure 6E). We concluded
that a decrease in Aurora-A levels or dissociation of N-MYC/
Aurora-A complexes promotes stable association of TFIIIC
and RAD21 with N-MYC-bound loci in S phase; it is also
possible that inhibition of Aurora-A-dependent TFIIIC2 phos-
phorylation contributes to the increase. Notably, chromatin
association of TFIIIC also increased in response to CD532
on sites where no N-MYC peak was detected in ChIP
sequencing (Figure S6E). It is possible, therefore, that
Aurora-A inhibits TFIIIC binding to chromatin also when com-
plexed by other transcription factors. However, removing the
inherent threshold in peak-calling algorithms revealed the
presence of N-MYC at the majority (26,165 of 36,736) of all
TFIIIC sites detectable after CD532 treatment (Figure S6F).
Most likely, therefore, N-MYC is associated with the majority
of all TFIIIC sites.is indicated in parallel. Error bars show SD of technical triplicates from one
nting cell cycle distribution at the indicated times after release from a double
-MYC and RAD21 and TOP2A and TFIIIC5 in IMR-5 cells at the indicated times
Red dots show PLA signals (n = 3).
l triplicates from one representative experiment (n = 3). **p < 0.01, ***p < 0.001.
nd TFIIIC5 at the indicated gene loci at the indicated times after release from a
resentative experiment (n = 3).
r each experiment.
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Figure 6. Role of Aurora-A in Dynamics of N-MYC Complexes during the Cell Cycle
(A) Immunoblot documenting levels of the indicated proteins and of Aurora-A, which is autophosphorylated at T288 (indicating catalytically active Aurora-A), in
IMR-5 MYCN-amplified neuroblastoma cells after 4 hr (left) or 24 hr (right) exposure to 1 mM of the indicated Aurora-A inhibitors (n = 4).
(legend continued on next page)
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Cell Cycle-Dependent Regulation of Pause Release by
Aurora-A
To understand the role of TFIIIC in N-MYC-dependent pause
release of Pol II, we analyzed SH-EP neuroblastoma cells, which
express an N-MYCER chimeric protein that can be activated by
addition of 4-Hydroxytamoxifen (4-OHT). We engineered these
cells to express a doxycycline-inducible shRNA targeting TFIIIC5
(Figure 7A) and performed ChIP sequencing with antibodies
directed against total Pol II before and 5 hr after addition of
4-OHT. Inspection of individual genes (ODC1 and NPM1) (Fig-
ure S7A) and global analyses (Figures 7B and 7C; Figure S7B)
showed that activation of N-MYC led to a strong decrease in
Pol II occupancy at the transcription start site and a correspond-
ing decrease in the Pol II ‘‘traveling ratio,’’ which is defined as the
ratio of Pol II occupancy at the promoter to occupancy in the
gene body (Rahl et al., 2010). Depletion of TFIIIC5 by itself
caused a moderate increase in Pol II promoter occupancy and
Pol II traveling ratio (Figures 7B and 7C; Figures S7A and S7B).
Intriguingly, depletion of TFIIIC5 abrogated the effect of
N-MYCER on Pol II (Figures 7B and 7C; Figures S7A and S7B).
To understand which of N-MYC’s effects on Pol II depend on
TFIIIC, we performed ChIPs using antibodies that specifically
recognize hypo-phosphorylated Pol II (8WG16) (Stock et al.,
2007) or Pol II phosphorylated at Ser5, which occurs during
escape of Pol II from the promoter, or at Ser2, which is a hallmark
of pause release of Pol II, respectively. Intriguingly, ChIP
sequencing showed that activation of N-MYC had no significant
effect on chromatin association of hypo-phosphorylated Pol II
(Figure S7C). To pinpoint the effect of N-MYC on Pol II function,
we analyzed the association of Pol II with several MYC target
genes for which Pol II does not decrease strongly at the promoter
after N-MYC activation. Consistent with the ChIP sequencing
data, neither activation of N-MYC nor depletion of TFIIIC5 had
a significant effect on the association of hypo-phosphorylated
Pol II with the transcription start site of several N-MYC target
genes (Figure 7D). In contrast, depletion of TFIIIC5 abrogated
both an N-MYC-dependent increase of Pol II that is phosphory-
lated at Ser5 at the transcription start site and of Pol II phosphor-
ylated at Ser2 at the transcription end site (Figure 7D).
Collectively, the data argue that TFIIIC5 is required for N-MYC-
dependent escape of Pol II from the promoter and the subse-
quent pause release of Pol II.
To understand whether N-MYC-dependent pause release is
cell cycle-regulated and whether Aurora-A affects this process,
we activated N-MYCER in cells synchronized in S phase by a
double thymidine block (Figures 7E and 7F). Under these circum-
stances, activation of N-MYC did not promote pause release of(B) Representative pictures from PLAs documenting complex formation between N
double thymidine block in the presence of the indicated Aurora-A inhibitors (1 m
signals arising from interaction of N-MYC with the indicated proteins.
(C) Quantification of PLAs shown in (B). Data are normalized to DMSO-treated ce
**p < 0.01, ***p < 0.001.
(D) Genome browser tracks at the PPRC1 locus, illustrating chromatin association
are indicated by vertical lines. The upper input is for ChIP sequencing of N-MYC
(E) ChIP of IMR-5 cells documenting chromatin association of N-MYC, TFIIIC5,
MLN8237 (24 hr), CD532 (4 hr), or DMSO as a control. Error bars show SEM of t
See also Figure S6. n indicates the number of independent biological replicas foPol II; rather, activation of N-MYC caused a slight global increase
in Pol II occupancy at core promoters, consistent with observa-
tions that MYC proteins can enhance promoter association of
Pol II (Jaenicke et al., 2016). To test whether Aurora-A is required
to block N-MYC-dependent pause release in S phase, we added
CD532 to synchronized cells and performed ChIP sequencing
both in the presence and absence of 4-OHT. Addition of
CD532 to cells with activated N-MYC globally enhanced associ-
ation of Pol II with the body of transcribed genes (Figure 7E; Fig-
ure S7D). In contrast, CD532 had little effect on Pol II function in
cells with inactive N-MYCER, arguing that the effects on Pol II are
mediated via N-MYC (Figure 7E; Figure S7D). CD532 also
enhanced association of Pol II with the promoter in a N-MYC-
dependent manner and, as consequence, did not alter the over-
all traveling ratio (Figure S7E). Furthermore, CD532 increased
chromatin association of pSer2-Pol II in the gene body and at
the transcription end site, and the effect was stronger in the pres-
ence of active N-MYC (Figure 7E). We concluded that associa-
tion with Aurora-A antagonizes N-MYC-dependent promoter
binding of Pol II and transcriptional elongation during S phase.
Finally, we explored a possible effect of enhanced transcrip-
tional elongation on DNA replication and monitored phosphory-
lation of the single-strand DNA binding protein RPA32 at S33,
which is phosphorylated by the ATR kinase in response to repli-
cation stress (Figure S7F; Liu et al., 2012). Inhibition of Aurora-A
during the release of IMR-5 cells from a double thymidine block
markedly enhanced phosphorylation of this site. In contrast, we
did not observe phosphorylation of RPA32 at S4 and S8, target
sites of DNA-dependent protein kinase (DNA-PK), and no activa-
tion of CHK1 and stabilization of p53 (Figure S7F). Consistently,
inhibition of Aurora-A perturbed S phase progression, but did not
prevent S phase entry or induce apoptosis (Figure S7G; Discus-
sion). A model summarizing our findings is shown in Figure 7G.
DISCUSSION
We performed a proteomic analysis of N-MYC complexes in
neuroblastoma cells and confirmed previously identified interac-
tions of MYC and N-MYC proteins with MAX, the NuA4 complex,
BPTF, p400, and the PAF1 complex. We also validated TFIIIC,
RAD21, and TOP2A as interaction partners of N-MYC, arguing
that N-MYC uses multiple effector proteins to regulate transcrip-
tion. Previous proteomic analyses demonstrated the presence of
TFIIIC and TOP2A in MYC complexes, suggesting that these in-
teractions are conserved with MYC proteins (Koch et al., 2007).
Our data provide insights into how MYC accelerates several
transitions of Pol II from one intermediate promoter state to the-MYC and RAD21 and TOP2A or TFIIIC5 in IMR-5 cells released for 4 hr from a
M) or DMSO as a control. Nuclei were stained using Hoechst. Red dots show
lls. Bars show mean + SD of technical triplicates from one experiment (n = 4).
of the indicated proteins. The positions of B- and E-boxes and of CTCF motifs
and TFIIIC5, the lower input is for ChIP-sequencing of RAD21 and CTCF.
and RAD21 at the indicated loci after treatment (1 mM) with MK-5108 (24 hr),
hree independent experiments. Data are normalized to DMSO-treated cells.
r each experiment.
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Figure 7. Aurora-A Suppresses N-MYC-Dependent Pause Release of Pol II in S phase
(A) Immunoblot showing levels of TFIIIC5 in SH-EP-N-MYCER cells expressing a Dox-inducible shRNA targeting TFIIIC5 (n = 3). Dox (1 mg ml1) was added for
30 hr; EtOH was used as a control.
(B) Metagene plot of all expressed genes (n = 14,650) illustrating distribution of Pol II within transcribed regions before and 5 hr after activation of N-MYCER in cells
expressing Dox-inducible shTFIIIC5.
(legend continued on next page)
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next. TFIIIC is both a general transcription factor of RNA poly-
merase III and an architectural protein (Van Bortle et al., 2014)
and has been linked to the function of both cohesin and conden-
sin complexes. In yeast, TFIIIC is required for loading condensin
complexes onto tRNA genes (D’Ambrosio et al., 2008). In
Drosophila, TFIIIC co-localizes with RAD21/cohesin at ETC sites
(Van Bortle et al., 2014). Our ChIP sequencing data showed that
N-MYC co-localizes with TFIIIC at multiple promoters and inter-
genic sites. TFIIIC is essential for transcription by RNA polymer-
ase III, but the precise function of TFIIIC at ETC sites is unknown.
We found that TFIIIC5 promotes association of RAD21 with
N-MYC-bound promoters and is required for N-MYC-dependent
phosphorylation of Pol II at Ser5 and Ser2 at several target
genes, arguing that it promotes both promoter escape and
pause release of Pol II. ChIP experiments suggest a hierarchy
in which N-MYC promotes binding of TFIIIC, and TFIIIC, in
turn, recruits RAD21. Because RAD21 and cohesin can promote
pause release of Pol II (Schaaf et al., 2013), we suggest that
N-MYC-dependent recruitment of RAD21 via TFIIIC facilitates
promoter escape and pause release of Pol II in an enhancer-
dependent manner. The model is consistent with the recent
observation that depletion of RAD21 represses expression of
N-MYC and MYC target genes (Rohban et al., 2017). Because
the identity of active enhancers is characteristic for each cell, a
model in which N-MYC facilitates the function of pre-existing en-
hancers could explain how N-MYC can ‘‘amplify’’ a pre-existing
gene expression program.
Topoisomerase I is activated at core promoters via direct as-
sociation with Pol II and promotes pause release because it re-
lieves the torsional stress that builds up during early stages of
transcription (Baranello et al., 2016). Because TOP2A associates
with promoters of highly transcribed genes (Kouzine et al., 2013),
it is likely that the association with N-MYC similarly relieves
torsional stress during early stages of transcription, suggesting
that multiple protein-protein interactions enable MYC proteins
to facilitate consecutive steps of transcription (Figure 7G).
Unexpectedly, complexes of N-MYC are highly dynamic dur-
ing the cell cycle. In vitro, Aurora-A competes with binding of
TFIIIC and RAD21 to the amino-terminus of N-MYC. A secondary
binding site for Aurora-A overlaps with MYCBoxIV, which binds
to HCF1, and it is possible, therefore, that Aurora-A also com-
petes with HCF1 for binding to N-MYC (Thomas et al., 2016).
In vivo, Aurora-A inhibits chromatin binding of TFIIIC and
RAD21 and interactions of N-MYC with RAD21, TOP2A, and(C) 2D kernel density plot showing the ratio of Pol II occupancy at the promoter
expressed genes (n = 14,650) before and after 5 hr of N-MYCER-activation.
(D). ChIP of SH-EPN-MYCER cells documenting chromatin association of hypo-p
the indicated gene loci before and 5 hr after activation of N-MYCER. Occupancy a
and pSer5Pol II. Occupancy at the transcription end site (TES) was analyzed for
Error bars show SD of technical triplicates from one representative experiment (
(E) Genome browser tracks illustrating chromatin association of Pol II and Pol II pS
in S phase by double thymidine blockade and treated for 2 hr with CD532 where
(F) 2D kernel density plot showing the Pol II traveling ratio in response to N-MY
thymidine block for all expressed genes (n = 14,650) before and after 4 hr of N-M
(G) Model summarizing our findings. We propose that the multiple protein-protein
both promotor escape and pause release. The dashed line indicates that effects
Ser5 phosphorylation. E/C indicates that the complex associates with sites on c
See also Figure S7. n indicates the number of independent biological replicas foTFIIIC in S phase (Figure 7G). N-MYC-dependent pause release
is inhibited in S phase, and inhibition of Aurora-A using CD532
partially restores elongation. Whymight this regulation be impor-
tant? Inhibition of Aurora-A during S phase activates the ATR ki-
nase, which monitors replication stress (Hamperl and Cimprich,
2016). Phosphorylation of RPA32 at S33 with no CHK1 phos-
phorylation, as observed here, has been linked to recovery of
collapsed replication forks rather than CHK1-mediated cell cycle
arrest and DNA repair (Shiotani et al., 2013). We hypothesize,
therefore, that MYC-dependent transcriptional elongation has
an inherent potential to cause conflicts with DNA replication
and that complex formation of N-MYC with Aurora-A is one of
several co-transcriptional mechanisms that prevent such con-
flicts (Hamperl and Cimprich, 2016). Notably, TFIIIC binding
was detected at many sites on chromatin at which we did not
detect N-MYC, and TFIIIC binding was regulated by Aurora-A
also at such sites. It is possible, therefore, that Aurora-A also reg-
ulates TFIIIC chromatin association independently of N-MYC.
However, removing the inherent threshold in peak calling re-
vealed the presence of N-MYC at the majority of all TFIIIC sites.
Inhibition of Aurora-A shows therapeutic efficacy in multiple
MYC- and N-MYC-driven tumor models (Dardenne et al., 2016;
Dauch et al., 2016). Similarly, deregulated expression of MYC
and N-MYC activates ATR, and inhibition of ATR or CHK1 are
being explored as possible therapeutic strategies for MYC-
and N-MYC-driven tumors (Cole et al., 2011; Murga et al.,
2011). Our findings suggest that MYC-driven tumors are partic-
ularly dependent on Aurora-A to avoid transcription/replication
conflicts and open the possibility for rational development of
therapies targeting these tumors.
EXPERIMENTAL PROCEDURES
Further details and an outline of the resources used in this work can be found in
the Supplemental Experimental Procedures.
Cell Culture and Cell Cycle Synchronization
Neuroblastoma cell lines (IMR-5, IMR-32, and SH-EP) were grown in RPMI-
1640 supplemented with 10% fetal calf serum and penicillin/streptomycin.
For synchronization in S phase, cellswere treated for 16 hrwith 2mM thymidine,
released for 8 hr into normal medium, and then blocked again (2mM, 16 hr). For
release, cells were washed with PBS before fresh medium was added.
High-Throughput Sequencing
ChIP and ChIP sequencing were performed as described previously (Walz
et al., 2014). RNA sequencing was performed as described previouslyto occupancy in the gene body (traveling ratio) in cells treated as above for all
hosphorylated Pol II and Pol II phosphorylated at Ser5 (pSer5) or Ser2 (pSer2) at
t the transcription start site (TSS) was analyzed for hypo-phosphorylated Pol II
pSer2Pol II. Dox (1 mg ml1) was added for 30 hr; EtOH was used as a control.
n = 3).
er2 at theODC1 locus. ChIP sequencing was performed on cells synchronized
indicated (1 mM).
CER activation in SH-EP cells that were synchronized in S phase by double
YCER activation.
interactions of N-MYC promote sequential phosphorylation events of Pol II and
on pause release and Ser2 phosphorylation could be secondary to changes in
hromatin that contain either an E-box or a CTCF motif.
r each experiment.
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(Jaenicke et al., 2016) using an IlluminaNextSeq 500. Preparations of samples,
data quality assessment, filtering, and mapping are described in the Supple-
mental Experimental Procedures.
In Situ PLA
The PLAwas performed using the Duolink In SituKit (Sigma-Aldrich) according
to the manufacturer’s protocol. Pictures were taken with a confocal micro-
scope (Nikon Ti-Eclipse) at 603 magnification. For quantification, the dots in
not less than 300 cells were counted using ImageJ (Wayne Rasband, NIH). An-
tibodies are listed in the resource table in the Supplemental Experimental
Procedures.
Statistical Methods
Statistical significance between experimental groups was determined by Stu-
dent’s t test or, when means of three or more groups were compared, by one-
way ANOVA. Data analysis was performedwith Prism5.0 software (GraphPad).
p < 0.05 was considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA and ChIP sequencing data reported in this
paper is GEO: GSE78957.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.11.090.
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